Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

A Phase I Study of Hydroxychloroquine with Infusional Cyclophosphamide, Pulse Dexamethasone and Rapamycin in Patients with Relapsed or Refractory Multiple Myeloma

Emma C. Scott, MD, Dan T. Vogl, MD MSCE, Shara Reasor-Heard, Kevin Floyd, Eva Medvedova, MD, Stephen E. Spurgeon, MD, Miranda Gordon, RN, Anne Kratz, RN, Matthew B. Siegel, MD, Marc Loriaux, MD PhD, Phoebe Trubowitz, MD, Stephen D Smith, MD, Selina Qiuying Liu, Ranjana Arora, MD, Edward A. Stadtmauer, Ravi K. Amaravadi, MD, Richard T. Maziarz, MD

Blood (2014) 124 (21): 3449.

https://doi.org/10.1182/blood.V124.21.3449.3449

Published: 2014

Journal Articles

Combined Autophagy and Proteasome Inhibition for Multiple Myeloma: Final Results of a Phase 1 Trial of Hydroxychloroquine and Standard Dose Bortezomib for Patients with Relapsed or Refractory Myeloma

Dan T. Vogl, MD, MSCE, Edward A. Stadtmauer, MD, James Bradner, MD, Lisa Davis, PharmD, Thomas M. Paul, Emma C. Scott, MD, Charles W. Nichols, MD, David L. Porter, MD, Martin Carroll, MD, Janeen Kaplan, Gayle Mallon, Cezary R. Swider, Patricia A. Mangan, Brenda K. Shelly, Ravi K. Amaravadi, MD

Blood (2011) 118 (21): 1869.

https://doi.org/10.1182/blood.V118.21.1869.1869

Published: 2011

Journal Articles

The Rationale for Combined Proteasome and Autophagy Inhibition in Multiple Myeloma Established Using Novel Translational Platforms

John Paul Y.C. Shen, M.D., Sanjay Divakaran, B.S., Sridevi Ponduru, M.D., Dan T. Vogl, MD, Ravi K. Amaravadi, M.D., James E. Bradner, M.D.

Blood (2008) 112 (11): 2755.

https://doi.org/10.1182/blood.V112.11.2755.2755

Published: 2008

Journal Articles

Combined Autophagy and Proteasome Inhibition for Multiple Myeloma: Preliminary Results of a Phase 1/2 Trial of Hydroxychloroquine and Standard Dose Bortezomib for Relapsed or Refractory Myeloma

Dan T. Vogl, Edward A. Stadtmauer, James E. Bradner, Lisa Davis, Martin Carroll, Charles W. Nichols, Doris Shank, Mary Carberry, Cezary R. Swider, Patricia A. Mangan, Brenda K. Shelly, Craig B. Thompson, Ravi K. Amaravadi

Blood (2008) 112 (11): 3684.

https://doi.org/10.1182/blood.V112.11.3684.3684

Published: 2008

Journal Articles

Chloroquine Inhibits Autophagy, Enhances p53-Dependent Apoptosis, and Delays Tumor Recurrence in a Mouse Model of B Cell Lymphoma.

Ravi K. Amaravadi, MD, Duonan Yu, PhD, Andrei Thomas-Tikhonenko, PhD, Craig B. Thompson, MD

Blood (2005) 106 (11): 2421.

https://doi.org/10.1182/blood.V106.11.2421.2421

Published: 2005

Journal Articles

Cell Proliferation Induced by the NPM-ALK Fusion Tyrosine Kinase of Anaplastic Large Cell Lymphoma Is Mediated by mTOR/S6K1 and MEK/ERK Signaling.

Ravi K. Amaravadi, MD, Naznin Haq, Stephan W. Morris, MD, D. Gary Gilliland, PhD, MD, David W. Sternberg, MD, PhD

Blood (2004) 104 (11): 241.

https://doi.org/10.1182/blood.V104.11.241.241

Published: 2004

NARROW

A Phase I Study of Hydroxychloroquine with Infusional Cyclophosphamide, Pulse Dexamethasone and Rapamycin in Patients with Relapsed or Refractory Multiple Myeloma

Combined Autophagy and Proteasome Inhibition for Multiple Myeloma: Final Results of a Phase 1 Trial of Hydroxychloroquine and Standard Dose Bortezomib for Patients with Relapsed or Refractory Myeloma

The Rationale for Combined Proteasome and Autophagy Inhibition in Multiple Myeloma Established Using Novel Translational Platforms

Combined Autophagy and Proteasome Inhibition for Multiple Myeloma: Preliminary Results of a Phase 1/2 Trial of Hydroxychloroquine and Standard Dose Bortezomib for Relapsed or Refractory Myeloma

Chloroquine Inhibits Autophagy, Enhances p53-Dependent Apoptosis, and Delays Tumor Recurrence in a Mouse Model of B Cell Lymphoma.

Cell Proliferation Induced by the NPM-ALK Fusion Tyrosine Kinase of Anaplastic Large Cell Lymphoma Is Mediated by mTOR/S6K1 and MEK/ERK Signaling.

Email alerts

ASH Publications

American Society of Hematology

A Phase I Study of Hydroxychloroquine with Infusional Cyclophosphamide, Pulse Dexamethasone and Rapamycin in Patients with Relapsed or Refractory Multiple Myeloma

Combined Autophagy and Proteasome Inhibition for Multiple Myeloma: Final Results of a Phase 1 Trial of Hydroxychloroquine and Standard Dose Bortezomib for Patients with Relapsed or Refractory Myeloma

The Rationale for Combined Proteasome and Autophagy Inhibition in Multiple Myeloma Established Using Novel Translational Platforms

Combined Autophagy and Proteasome Inhibition for Multiple Myeloma: Preliminary Results of a Phase 1/2 Trial of Hydroxychloroquine and Standard Dose Bortezomib for Relapsed or Refractory Myeloma

Chloroquine Inhibits Autophagy, Enhances p53-Dependent Apoptosis, and Delays Tumor Recurrence in a Mouse Model of B Cell Lymphoma.

Cell Proliferation Induced by the NPM-ALK Fusion Tyrosine Kinase of Anaplastic Large Cell Lymphoma Is Mediated by mTOR/S6K1 and MEK/ERK Signaling.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only